ストックスクリーナーアプリを入手
29.25
1.35%
0.389
アフターアワーズ：
28.90
-0.349
-1.19%
前日終値:
$28.86
開ける：
$28
24時間の取引高:
8.58M
Relative Volume:
7.47
時価総額：
$1.94B
収益：
-
当期純損益:
$-119.67M
株価収益率:
-10.71
EPS:
-2.73
ネットキャッシュフロー:
$-97.30M
1週間 パフォーマンス:
+92.30%
1か月 パフォーマンス:
+114.04%
6か月 パフォーマンス:
+227.17%
1年 パフォーマンス:
+144.76%
1日の値動き範囲:
$27.08
$32.00
1週間の範囲:
$14.94
$32.00
52週間の値動き範囲:
$8.241
$32.00
Mineralys Therapeutics Inc Stock (MLYS) Company Profile
名前
Mineralys Therapeutics Inc
セクター
電話
(888) 378-6240
住所
150 N. RADNOR CHESTER ROAD, RADNOR
MLYS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MLYS
Mineralys Therapeutics Inc
|
29.25 | 1.03B | 0 | -119.67M | -97.30M | -2.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.62 | 100.25B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.80 | 61.55B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
447.23 | 58.53B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
722.01 | 43.59B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
336.26 | 33.67B | 3.81B | -644.79M | -669.77M | -6.24 |
Mineralys Therapeutics Inc Stock (MLYS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-06-11 | 開始されました | Jefferies | Hold |
| 2024-07-10 | 開始されました | H.C. Wainwright | Buy |
| 2024-04-02 | 開始されました | Goldman | Buy |
| 2023-03-07 | 開始されました | BofA Securities | Buy |
| 2023-03-07 | 開始されました | Credit Suisse | Outperform |
| 2023-03-07 | 開始されました | Evercore ISI | Outperform |
| 2023-03-07 | 開始されました | Guggenheim | Buy |
| 2023-03-07 | 開始されました | Stifel | Buy |
| 2023-03-07 | 開始されました | Wells Fargo | Overweight |
すべてを表示
Mineralys Therapeutics Inc (MLYS) 最新ニュース
Mineralys: Soaring As Rival's Hypertension Data Falls ShortBuy The Next Dip (MLYS) - Seeking Alpha
Can volume confirm reversal in Mineralys Therapeutics Inc.Product Launch & Accurate Buy Signal Alerts - Newser
Mineralys In The Money As Lorundrostat Gets Close To Market - insights.citeline.com
Mineralys’ strategic stock sale; Gilead, Shoreline partnership ends - Endpoints News
Mineralys (MLYS) Steals Spotlight From AstraZeneca, Reaches Fresh Peak - Yahoo Finance
Mineralys Therapeutics prices upsized $250M stock offering - MSN
Short interest data insights for Mineralys Therapeutics Inc.July 2025 Gainers & Free Reliable Trade Execution Plans - Newser
How to interpret RSI for Mineralys Therapeutics Inc. stockM&A Rumor & Risk Managed Investment Entry Signals - Newser
Institutional scanner results for Mineralys Therapeutics Inc.Portfolio Return Report & Long-Term Growth Plans - Newser
Can Mineralys Therapeutics Inc. disrupt its industryGold Moves & Growth Focused Entry Point Reports - khodrobank.com
Bruker, Mineralys Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
Identifying reversal signals in Mineralys Therapeutics Inc.2025 Key Lessons & Safe Entry Trade Signal Reports - Newser
Jefferies raises Mineralys Therapeutics stock price target to $26 from $15 - Investing.com
Will Mineralys Therapeutics Inc. announce a stock splitPortfolio Gains Summary & Technical Pattern Recognition Alerts - khodrobank.com
Mineralys Therapeutics shares fall 6.38% premarket after suspending prospectus supplement for ATM equity offering. - AInvest
Is Mineralys Therapeutics Inc. still worth holding after the dip2025 Trade Ideas & Weekly Top Performers Watchlists - Newser
Q&A with Jon Congleton, CEO of Mineralys Therapeutics - The Pharma Letter
Order flow analysis tools used on Mineralys Therapeutics Inc.Weekly Market Outlook & Stepwise Trade Signal Implementation - Newser
What high frequency data says about Mineralys Therapeutics Inc.July 2025 PreEarnings & Long-Term Investment Growth Plans - Newser
Mineralys Therapeutics Prices $250 Million Notes Offering - MarketScreener
Mineralys Therapeutics stock hits all-time high at 22.0 USD By Investing.com - Investing.com Canada
What MACD and RSI say about Mineralys Therapeutics Inc.Earnings Overview Summary & Weekly Watchlist for Consistent Profits - Newser
How sentiment analysis helps forecast Mineralys Therapeutics Inc.July 2025 Reactions & Low Risk Entry Point Guides - Newser
Published on: 2025-09-03 02:21:26 - Newser
How moving averages guide Mineralys Therapeutics Inc. tradingEarnings Overview Report & Safe Entry Point Identification - Newser
Key metrics from Mineralys Therapeutics Inc.’s quarterly dataJuly 2025 Drop Watch & Stepwise Trade Execution Plans - Newser
Chart overlay techniques for tracking Mineralys Therapeutics Inc.Quarterly Market Summary & Daily Price Action Insights - Newser
Using RSI to spot recovery in Mineralys Therapeutics Inc.July 2025 Patterns & Technical Confirmation Trade Alerts - Newser
Mineralys Therapeutics' $250M Upsized Equity Raise: A Strategic Inflection Point for Hypertension Innovation - AInvest
Published on: 2025-09-03 00:47:22 - Newser
Published on: 2025-09-03 00:45:39 - Newser
Jefferies expects Mineralys stock to trade up following AstraZeneca data - MSN
$250 Million Stock Offering: Hypertension Drug Developer Mineralys Prices Upsized Public Share Sale - Stock Titan
Mineralys Therapeutics Prices Upsized Public Offering Of 9.80 Mln At $25.50/shr - Nasdaq
Mineralys Therapeutics Announces Upsized Public Offering of Common Stock Raising Approximately $250 Million - Quiver Quantitative
Mineralys Therapeutics announces pricing of upsized $250.0 million underwritten public offering of common stock - MarketScreener
Mineralys Therapeutics Announces Pricing of Upsized $250.0 Million Underwritten Public Offering of Common Stock - GlobeNewswire
Does Mineralys Therapeutics Inc. align with a passive investing strategyQuarterly Profit Summary & Advanced Swing Trade Entry Alerts - khodrobank.com
Mineralys Stock Surges 86.43% on $0.43B Trading Volume Ranked 256th in Market Activity as $175M Public Offering Drives Institutional Confidence - AInvest
Mineralys Therapeutics to Announce Q2 Financial Results on August 12 - MSN
AstraZeneca's Blood Pressure Drug Baxdrostat Shows Positive Trial Results, Boosting Mineralys Therapeutics Shares by 85% - AInvest
Mineralys Therapeutics announces proposed public offering of common stock - MarketScreener
Mineralys Therapeutics Halts Common Stock Offering - TipRanks
Mineralys Therapeutics down on $175 mln stock offering plans - TradingView
Is Mineralys Therapeutics Inc. reversing from oversold territory2025 Stock Rankings & Low Drawdown Momentum Ideas - Newser
Mineralys Therapeutics launches $175 million public stock offering - Investing.com
Mineralys Therapeutics Launches $175 Million Public Share Offering - MarketScreener
Mineralys Therapeutics announces $175M common stock offering - TipRanks
Mineralys Therapeutics Announces Proposed Public Offering of Common Stock - GlobeNewswire
$175 Million Stock Offering: Mineralys Therapeutics Seeks Funding for Hypertension Drug Development - Stock Titan
Mineralys surges after late-stage trial data AstraZeneca’s blood pressure drug - MSN
Mineralys Therapeutics Inc (MLYS) 財務データ
収益
当期純利益
現金流量
EPS
1.14%
1.34%
大文字化:
|
ボリューム (24 時間):